The role of chemokines and chemokine receptors in multiple sclerosis

Cui, Lianxian; Chu, Shifeng; Chen, Nai‐Hong

doi:10.1016/j.intimp.2020.106314

Cited by 92 publications

(63 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, it has also been reported that C1P promotes macrophage chemoattractant protein-1 (MCP-1) released in different types of cells, and this chemokine was revealed to be a major mediator of C1P-stimulated cell migration events ( 54 , 55 ). However, C1P-stimulated macrophage migration could be blocked by PA, a glycerophospholipid structurally related to C1P ( 56 ).…”

Section: Discussionmentioning

confidence: 99%

Distinctive sphingolipid patterns in chronic multiple sclerosis lesions

Podbielska

Szulc

Ariga

et al. 2020

Journal of Lipid Research

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a CNS disease characterized by immune-mediated demyelination and progressive axonal loss. MS-related CNS damage and its clinical course have two main phases: active and inactive/progressive. Reliable biomarkers are being sought to allow identification of MS pathomechanisms and prediction of its course. The purpose of this study was to identify sphingolipid (SL) species as candidate biomarkers of inflammatory and neurodegenerative processes underlying MS pathology. We performed sphingolipidomic analysis by high-performance liquid chromatography-tandem mass spectrometry to determine the lipid profiles in post mortem specimens from the normal appearing white matter (NAWM) of normal CNS (nCNS), from subjects with chronic MS (active and inactive lesions) as well as from patients with other neurological diseases. Distinctive SL modification patterns occurred in specimens from MS patients with chronic inactive plaques with respect to NAWM from nCNS and active MS lesions. Chronic inactive MS lesions were characterized by decreased level of dihydroceramide (dhCer), ceramide, and sphingomyelin subspecies whereas level of hexosylceramide and ceramide-1-phosphate (C1P) subspecies was significantly increased in comparison to NAWM of nCNS as well as active MS plaques. In contrast, active MS lesions were characterized by a significant increase of major dhCer subspecies in comparison to NAWM of nCNS. These results suggest the existence of different SL metabolic pathways in the active versus inactive phase within progressive stage of MS. Moreover, they suggest that C1P could be a new biomarker of inactive MS progressive phase, and its detection may help to develop future prognostic and therapeutic strategies for the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Distinctive sphingolipid patterns in chronic multiple sclerosis lesions

Podbielska

Szulc

Ariga

et al. 2020

Journal of Lipid Research

View full text Add to dashboard Cite

show abstract

“…Table 1 demonstrates the recent understanding of the 4 chemokine subfamilies and their receptors (for reviews, please see). [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]…”

Section: Targeting Chemokines and Chemokine Receptors As Immunotherapmentioning

confidence: 99%

“…Chemokines and their receptors are increasingly expressed in MS patients. 30 The chemokines/chemokine receptors axis expressed in T cells have the capability of recruiting inflammatory cells into CNS, which may lead to its destruction. 26,30 Different chemokines play pathogenic roles in MS.…”

Section: Role Of Chemokines In the Pathophysiology Of Msmentioning

confidence: 99%

“…30 The chemokines/chemokine receptors axis expressed in T cells have the capability of recruiting inflammatory cells into CNS, which may lead to its destruction. 26,30 Different chemokines play pathogenic roles in MS. These include CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL17, CCL19, CCL21, CCL22, CXCL1, CXCL8, CXCL9, CXCL10, CXCL11, and CXCL16.…”

Section: Role Of Chemokines In the Pathophysiology Of Msmentioning

confidence: 99%

“…45,46 One study demonstrated that CCR1 is implicated in the pathogenesis of EAE using the CCR1 antagonist BX 471 which showed strong therapeutic effects in EAE animals. 47 CCL3 was identified as a macrophage-derived inflammatory mediator 48 and has been shown to be implicated in the pathophysiology of MS. 30 For instance, treatment of EAE -Functions as a cell survival factor.…”

Section: Targeting Of Chemokines and Chemokine Receptors Involved In mentioning

confidence: 99%

See 2 more Smart Citations

<p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis</p>

Dhaiban

Al‐Ani

Elemam

et al. 2020

JIR

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disorder that results in inflammation and demyelination of the central nervous system (CNS). MS symptoms include walking difficulties, visual weakening, as well as learning and memory impairment, thus affecting the quality of the patient's life. Chemokines and chemokine receptors are expressed on the immune cells as well as the CNS resident cells. Several sets of chemokine receptors and their ligands tend to be pathogenic players in MS, including CCL2,

show abstract

Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis

Jalaleddini,

Jakimovski,

Keshavan

et al. 2024

Ann Clin Transl Neurol

View full text Add to dashboard Cite

BackgroundA quantitative measurement of serum proteome biomarkers that would associate with disease progression endpoints can provide risk stratification for persons with multiple sclerosis (PwMS) and supplement the clinical decision‐making process.Materials and MethodsIn total, 202 PwMS were enrolled in a longitudinal study with measurements at two time points with an average follow‐up time of 5.4 years. Clinical measures included the Expanded Disability Status Scale, Timed 25‐foot Walk, 9‐Hole Peg, and Symbol Digit Modalities Tests. Subjects underwent magnetic resonance imaging to determine the volumetric measures of the whole brain, gray matter, deep gray matter, and lateral ventricles. Serum samples were analyzed using a custom immunoassay panel on the Olink™ platform, and concentrations of 18 protein biomarkers were measured. Linear mixed‐effects models and adjustment for multiple comparisons were performed.ResultsSubjects had a significant 55.6% increase in chemokine ligand 20 (9.7 pg/mL vs. 15.1 pg/mL, p < 0.001) and neurofilament light polypeptide (10.5 pg/mL vs. 11.5 pg/mL, p = 0.003) at the follow‐up time point. Additional changes in CUB domain‐containing protein 1, Contactin 2, Glial fibrillary acidic protein, Myelin oligodendrocyte glycoprotein, and Osteopontin were noted but did not survive multiple comparison correction. Worse clinical performance in the 9‐HPT was associated with neurofilament light polypeptide (p = 0.001). Increases in several biomarker candidates were correlated with greater neurodegenerative changes as measured by different brain volumes.ConclusionMultiple proteins, selected from a disease activity test that represent diverse biological pathways, are associated with physical, cognitive, and radiographic outcomes. Future studies should determine the utility of multiple protein assays in routine clinical care.

show abstract

The role of chemokines and chemokine receptors in multiple sclerosis

Cited by 92 publications

References 128 publications

Distinctive sphingolipid patterns in chronic multiple sclerosis lesions

Distinctive sphingolipid patterns in chronic multiple sclerosis lesions

<p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis</p>

Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis

Contact Info

Product

Resources

About